^
Association details:
| Biomarker: | LY9 expression |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug Class: | CAR-T immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma
Published date:
11/04/2021
Excerpt:
Here, a 71-year-old patient with CLL had an initial response when treated with CD19 CAR T cells but quickly relapsed only 2 months after treatment. Malignant cells from the CLL patient retained CD229 expression as identified by flow cytometry and an ex vivo coculture with CD229 CAR T cells revealed robust killing of CLL cells by CD229 CAR T cells.
DOI:
10.1182/blood-2021-154503
